26 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
Novartis Institutes For Biomedical Research
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
Abbvie
Integrated Platform for Expedited Synthesis-Purification-Testing of Small Molecule Libraries.
Abbvie
Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Chinese Academy of Sciences
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Korea Research Institute of Chemical Technology
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field.
Novartis Institutes for Biomedical Research
Triazole-fused pyrimidines in target-based anticancer drug discovery.
Zhenzhou University
Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma.
Zhengzhou University
An overview of the development of EED inhibitors to disable the PRC2 function.
University of Jinany
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
"Sapienza" University of Rome
Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
University of Naples "Federico Ii
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
The Affiliated Hospital of Qingdao University
Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Sanquan College of Xinxiang Medical University
Targeting EZH2 for cancer therapy: From current progress to novel strategies.
West China Hospital
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
Nanjing University of Chinese Medicine
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
Astrazeneca
Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.
University of Tennessee Health Science Center
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
Astrazeneca
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Northwestern University
EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.
University of Michigan
Methyllysine binding domains: Structural insight and small molecule probe development.
University of Connecticut
Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase.
Novartis Institutes For Biomedical Research
Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program.
Abbvie
Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
Merck Sharp & Dohme